{"id":"esomeprazole-na","safety":{"commonSideEffects":[{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"2-5%","effect":"Nausea"},{"rate":"2-5%","effect":"Abdominal pain"},{"rate":"2-5%","effect":"Constipation"},{"rate":"1-2%","effect":"Hypomagnesemia"}]},"_chembl":{"chemblId":"CHEMBL5314366","moleculeType":"Small molecule","molecularWeight":"769.20"},"_dailymed":{"setId":"4c25c106-b5ca-079f-e063-6394a90a4978","title":"NAPROXEN AND ESOMEPRAZOLE MAGNESIUM TABLET, DELAYED RELEASE [PHOENIX RX LLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Esomeprazole is the active S-enantiomer of omeprazole that irreversibly inhibits the H+/K+-ATPase enzyme (proton pump) on the secretory surface of gastric parietal cells. This blocks the final step of gastric acid production, reducing intragastric acidity. The sodium salt formulation allows for rapid intravenous administration, making it suitable for acute acid-related conditions where oral therapy is not feasible.","oneSentence":"Esomeprazole sodium inhibits gastric acid secretion by blocking the proton pump in parietal cells of the stomach.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:46:23.634Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastroesophageal reflux disease (GERD)"},{"name":"Peptic ulcer disease"},{"name":"Zollinger-Ellison syndrome"},{"name":"Prevention of gastric ulcers in patients receiving NSAIDs"},{"name":"Acute erosive esophagitis"}]},"trialDetails":[{"nctId":"NCT01757275","phase":"PHASE3","title":"High Dose Esomeprazole Na for Prevention of Rebleeding After Successful Endoscopic Therapy of a Bleeding Peptic Ulcer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2013-02","conditions":"Bleeding Peptic Ulcer","enrollment":239},{"nctId":"NCT00282555","phase":"PHASE2","title":"Efficiency Study of S-Tenatoprazole-Na to Treat Erosive or Ulcerative Esophagitis","status":"SUSPENDED","sponsor":"STEBA France","startDate":"2006-02","conditions":"Esophagitis, Reflux","enrollment":450}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Nexium"],"phase":"marketed","status":"active","brandName":"Esomeprazole Na","genericName":"Esomeprazole Na","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Esomeprazole sodium is used to prevent rebleeding after successful endoscopic therapy of a bleeding peptic ulcer and to treat conditions such as esophagitis and reflux. It is a medication that works by inhibiting the H+/K+ ATPase enzyme, which is involved in the production of stomach acid.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}